Q2 2026 Camurus AB Earnings Call Transcript
Key Points
- Camurus AB (CAMRF) reported a solid second quarter with total revenues of 702 million SEK, marking a 4% year-on-year and 32% sequential increase.
- The company achieved a record product sales of 528 million SEK, surpassing half a billion in a quarter for the first time.
- Brixadi royalties in the US increased by 42%, indicating strong growth in the US market.
- Camurus AB (CAMRF) remains debt-free, providing financial flexibility for future investments and growth opportunities.
- The company has a strong cash position of 4.1 billion SEK, up from 3.9 billion SEK at the start of the quarter, reflecting robust cash flow from operations.
- Camurus AB (CAMRF) received a complete response letter (CRL) for the acromegaly MDA in the US, indicating regulatory challenges.
- Marketing and distribution expenses rose significantly from 108 million SEK to 175 million SEK, reflecting increased commercial operations costs.
- R&D costs declined from 172 million SEK to 125 million SEK, which may indicate a reduction in research activities following the completion of multiple trials.
- The company faces capacity constraints in Australia, limiting the growth potential for Buvidal in the region.
- The FDA issued a CRL related to manufacturing observations, which could delay the US approval process for CAM2029.
Good afternoon, and welcome to Cameros Q2 Report 2026. During the questions and answer session, participants on the telco are able to ask questions by dialing pound key five on the telephone keypad. Now, I will hand the conference over to CEO, Krik Thiebet. Please go ahead.
Thank you so much, and good day, everyone, and welcome to Camero's second quarter 2026 result call.
Thank you for joining us.
Before we begin, please take note of our forward-looking statements, which apply throughout today's presentation.
So turning to the agenda, we will start with highlights, moving over to financial and commercial performance reviews, before finishing with a short R&D pipeline update, key takeaways, and then, of course, Q&A.
With me on the call today are Andres Wadsholt, our Chief Financial Officer, and Richard Jameson, our Chief Commercial Officer.
So let me start with some highlights.
I'm very pleased
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
